{"id":"NCT03651765","sponsor":"Rhythm Pharmaceuticals, Inc.","briefTitle":"Long Term Extension Trial of Setmelanotide","officialTitle":"Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-07-15","primaryCompletion":"2025-01-09","completion":"2025-01-09","firstPosted":"2018-08-29","resultsPosted":"2025-05-31","lastUpdate":"2025-05-31"},"enrollment":205,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Obesity Associated With Defects in Leptin-melanocortin Pathway"],"interventions":[{"type":"DRUG","name":"Setmelanotide","otherNames":["RM-493"]}],"arms":[{"label":"Setmelanotide","type":"EXPERIMENTAL"}],"summary":"This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the leptin-melanocortin pathway.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From first dose up to 5.6 years","effectByArm":[{"arm":"Setmelanotide","deltaMin":198,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":27,"countries":["United States","Canada","France","Germany","Greece","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["38697184","35112343"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":205},"commonTop":["Skin Hyperpigmentation","Covid-19","Headache","Injection Site Erythema","Melanocytic Naevus"]}}